Orexo Reaches Agreement in Principle with US Department of Justice
Swedish pharmaceutical company Orexo AB has reached a non-binding agreement in principle with the US Department of Justice (DOJ) regarding an ongoing investigation. The company is in the final stages of settlement discussions.
Uppsala, Sweden – Orexo AB (STO: ORX) (OTCQX: ORXOY) announced on September 1, 2026, that it has reached a non-binding agreement in principle on the main elements of a settlement with the US Department of Justice (DOJ). The company stated it is in the final stages of concluding this agreement.
The agreement concerns an investigation into Orexo's operations in the United States. While specific details of the settlement have not been disclosed, the company has been cooperating with the DOJ to resolve the matter. This development follows previous legal challenges faced by the company in the US market.
Orexo has indicated that the final terms and financial implications of the settlement will be announced once a definitive agreement has been executed and approved. The company previously stated its commitment to transparency throughout the process.
Orexo AB is a Swedish pharmaceutical company focused on developing and commercializing novel therapies for the treatment of pain and addiction. Its shares are listed on the Nasdaq Stockholm and traded over-the-counter in the US.